• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型益生菌疗法在结肠炎小鼠模型中的应用。

A novel probiotic therapeutic in a murine model of colitis.

机构信息

Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Department of Pediatric Surgery, Nationwide Children's Hospital , Columbus, OH, USA.

Center for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, OH, USA.

出版信息

Gut Microbes. 2020 Nov 9;12(1):1814119. doi: 10.1080/19490976.2020.1814119.

DOI:10.1080/19490976.2020.1814119
PMID:32954922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7524353/
Abstract

For prophylactic therapy, mice received an oral antibiotic cocktail followed by clindamycin injection, followed by probiotic administration (planktonic . biofilm state), followed by oral gavage. For treatment therapy, mice received antibiotics and first, followed by probiotic administration. Clinical sickness scores (CSS) and intestinal histologic injury scores (HIS) were assigned. In the model, CSS: 67% of untreated mice exposed to demonstrated CSS ≥ 6, which is consistent with infection (< .001 compared to unexposed mice). In mice treated with planktonic , 55% had a CSS ≥ 6, but only 19% of mice treated with in its biofilm state had CSS ≥ 6 (< .001). Mice receiving + DM-Maltose lost the least amount of weight compared to mice receiving saline ( = .004676) or to mice receiving (= .003185). HIS: 77% of untreated mice exposed to had HIS scores ≥4, which is consistent with infection. In mice treated with planktonic , 62% had HIS ≥4, but only 19% of mice treated with in its biofilm state had HIS ≥4. (< .001). Additionally, mice treated with in its biofilm state had better survival compared to untreated mice and to mice treated with planktonic ( ≤ 0.05). Similar findings for weight loss, CSS, HIS and survival were obtained for . A single dose of in its biofilm state reduces the severity and incidence of experimental infection when administered as both prophylactic and treatment therapy.

摘要

对于预防治疗,小鼠接受口服抗生素鸡尾酒,然后注射克林霉素,然后给予益生菌(浮游生物、生物膜状态),然后口服灌胃。对于治疗治疗,小鼠接受抗生素和第一次治疗,然后给予益生菌。分配临床疾病评分(CSS)和肠道组织学损伤评分(HIS)。在该模型中,CSS:暴露于未处理的未处理的小鼠中有 67%表现出 CSS≥6,这与感染一致(<0.001与未暴露的小鼠相比)。在用浮游生物治疗的小鼠中,55%的小鼠 CSS≥6,但只有 19%的处于生物膜状态的小鼠 CSS≥6(<0.001)。与接受生理盐水(=0.004676)或接受(=0.003185)的小鼠相比,接受+DM-麦芽糖的小鼠体重减轻最少(=0.004676)。HIS:暴露于未处理的小鼠中有 77%的 HIS 评分≥4,这与感染一致。在用浮游生物治疗的小鼠中,62%的 HIS≥4,但只有 19%的处于生物膜状态的小鼠 HIS≥4。(<0.001)。此外,与未处理的小鼠和用浮游生物治疗的小鼠相比,用生物膜状态治疗的小鼠具有更好的存活率(≤0.05)。对于体重减轻、CSS、HIS 和存活,也得到了类似的发现。生物膜状态下的单剂量可降低实验感染的严重程度和发生率,无论是预防治疗还是治疗治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/5d08fda94b39/KGMI_A_1814119_F0012_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/3774054e5b33/KGMI_A_1814119_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/387e404577e5/KGMI_A_1814119_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/b53afbb4d2c2/KGMI_A_1814119_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/18b79db7be81/KGMI_A_1814119_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/6733476acdba/KGMI_A_1814119_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/d2984b71d6df/KGMI_A_1814119_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/8d15db3d6dd3/KGMI_A_1814119_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/a5aea55732b2/KGMI_A_1814119_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/e570184abe1d/KGMI_A_1814119_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/22c103eac90d/KGMI_A_1814119_F0010_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/143c735c64a4/KGMI_A_1814119_F0011_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/5d08fda94b39/KGMI_A_1814119_F0012_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/3774054e5b33/KGMI_A_1814119_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/387e404577e5/KGMI_A_1814119_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/b53afbb4d2c2/KGMI_A_1814119_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/18b79db7be81/KGMI_A_1814119_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/6733476acdba/KGMI_A_1814119_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/d2984b71d6df/KGMI_A_1814119_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/8d15db3d6dd3/KGMI_A_1814119_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/a5aea55732b2/KGMI_A_1814119_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/e570184abe1d/KGMI_A_1814119_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/22c103eac90d/KGMI_A_1814119_F0010_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/143c735c64a4/KGMI_A_1814119_F0011_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0726/7524353/5d08fda94b39/KGMI_A_1814119_F0012_OC.jpg

相似文献

1
A novel probiotic therapeutic in a murine model of colitis.一种新型益生菌疗法在结肠炎小鼠模型中的应用。
Gut Microbes. 2020 Nov 9;12(1):1814119. doi: 10.1080/19490976.2020.1814119.
2
Development of a Standardized Scoring System to Assess a Murine Model of Colitis.开发一种标准化评分系统来评估结肠炎的小鼠模型。
J Invest Surg. 2020 Dec;33(10):887-895. doi: 10.1080/08941939.2019.1571129. Epub 2019 Mar 20.
3
Next-Generation Probiotic Therapy to Protect the Intestines From Injury.下一代益生菌疗法,保护肠道免受损伤。
Front Cell Infect Microbiol. 2022 Jun 28;12:863949. doi: 10.3389/fcimb.2022.863949. eCollection 2022.
4
An enhanced Lactobacillus reuteri biofilm formulation that increases protection against experimental necrotizing enterocolitis.增强型罗伊氏乳杆菌生物膜配方,可提高对实验性坏死性小肠结肠炎的保护作用。
Am J Physiol Gastrointest Liver Physiol. 2018 Sep 1;315(3):G408-G419. doi: 10.1152/ajpgi.00078.2018. Epub 2018 May 31.
5
The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.艰难梭菌感染小鼠模型中微生物组动态与病原体动态的相互作用。
Gut Microbes. 2011 May-Jun;2(3):145-58. doi: 10.4161/gmic.2.3.16333. Epub 2011 May 1.
6
Next-Generation Probiotics Targeting Clostridium difficile through Precursor-Directed Antimicrobial Biosynthesis.通过前体导向抗菌生物合成靶向艰难梭菌的下一代益生菌。
Infect Immun. 2017 Sep 20;85(10). doi: 10.1128/IAI.00303-17. Print 2017 Oct.
7
Antibacterial and anti-inflammatory effects of Lactobacillus reuteri in its biofilm state contribute to its beneficial effects in a rat model of experimental necrotizing enterocolitis.罗伊氏乳杆菌生物膜状态下的抑菌和抗炎作用有助于其在实验性坏死性小肠结肠炎大鼠模型中发挥有益作用。
J Pediatr Surg. 2022 Jul;57(7):1382-1390. doi: 10.1016/j.jpedsurg.2021.09.001. Epub 2021 Sep 20.
8
Superior performance of biofilm versus planktonic Limosilactobacillus reuteri in protection of the intestines and brain in a piglet model of necrotizing enterocolitis.在坏死性小肠结肠炎的仔猪模型中,生物膜形式的罗伊氏乳杆菌比浮游形式具有更好的保护肠道和大脑的性能。
Sci Rep. 2023 Oct 23;13(1):17740. doi: 10.1038/s41598-023-44676-5.
9
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.单次克林霉素给药导致肠道微生物群的深刻改变,从而使机体持续易患艰难梭菌诱导的结肠炎。
Infect Immun. 2012 Jan;80(1):62-73. doi: 10.1128/IAI.05496-11. Epub 2011 Oct 17.
10
Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes.艰难梭菌定植清除与抗生素特异性细菌变化相关。
mSphere. 2021 May 5;6(3):e01238-20. doi: 10.1128/mSphere.01238-20.

引用本文的文献

1
Dietary iron attenuates infection via modulation of intestinal immune response and gut microbiota.膳食铁通过调节肠道免疫反应和肠道微生物群来减轻感染。
Virulence. 2025 Dec;16(1):2529454. doi: 10.1080/21505594.2025.2529454. Epub 2025 Jul 16.
2
Modified probiotics and the related combinatorial therapeutics.改良益生菌及相关联合疗法。
Acta Pharm Sin B. 2025 May;15(5):2431-2453. doi: 10.1016/j.apsb.2025.03.021. Epub 2025 Mar 14.
3
Effects of Biofilm Formation on Gastrointestinal Tolerance, Mucoadhesion and Transcriptomic Responses of Probiotics.

本文引用的文献

1
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.益生菌预防儿童抗生素相关性腹泻
Cochrane Database Syst Rev. 2019 Apr 30;4(4):CD004827. doi: 10.1002/14651858.CD004827.pub5.
2
Development of a Standardized Scoring System to Assess a Murine Model of Colitis.开发一种标准化评分系统来评估结肠炎的小鼠模型。
J Invest Surg. 2020 Dec;33(10):887-895. doi: 10.1080/08941939.2019.1571129. Epub 2019 Mar 20.
3
Prolonged non-operative management of clostridium difficile colitis is associated with increased mortality, complications, and cost.
生物膜形成对益生菌胃肠道耐受性、黏膜黏附及转录组反应的影响
Food Sci Nutr. 2025 May 14;13(5):e70206. doi: 10.1002/fsn3.70206. eCollection 2025 May.
4
Probiotic biofilm modified scaffolds for facilitating osteomyelitis treatment through sustained release of bacteriophage and regulated macrophage polarization.用于通过噬菌体的持续释放和调节巨噬细胞极化促进骨髓炎治疗的益生菌生物膜修饰支架
Mater Today Bio. 2025 Jan 7;30:101444. doi: 10.1016/j.mtbio.2025.101444. eCollection 2025 Feb.
5
A commensal protozoan attenuates Clostridioides difficile pathogenesis in mice via arginine-ornithine metabolism and host intestinal immune response.一种共生原生动物通过精氨酸-鸟氨酸代谢和宿主肠道免疫反应来减轻小鼠艰难梭菌发病机制。
Nat Commun. 2024 Apr 2;15(1):2842. doi: 10.1038/s41467-024-47075-0.
6
Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder.一项针对自闭症谱系障碍参与者的 SB-121(一种研究性益生菌配方)的 Ib 期研究结果。
Sci Rep. 2023 Mar 30;13(1):5192. doi: 10.1038/s41598-023-30909-0.
7
The Mechanism of Important Components in Canine Fecal Microbiota Transplantation.犬粪便微生物群移植中重要成分的作用机制
Vet Sci. 2022 Dec 14;9(12):695. doi: 10.3390/vetsci9120695.
8
Metabolic Phenotyping Study of Mouse Brain Following Microbiome Disruption by Colonization.通过定殖破坏微生物群后小鼠大脑的代谢表型研究
Metabolites. 2022 Oct 28;12(11):1039. doi: 10.3390/metabo12111039.
9
Next-Generation Probiotic Therapy to Protect the Intestines From Injury.下一代益生菌疗法,保护肠道免受损伤。
Front Cell Infect Microbiol. 2022 Jun 28;12:863949. doi: 10.3389/fcimb.2022.863949. eCollection 2022.
10
Limosilactobacillus reuteri SLZX19-12 Protects the Colon from Infection by Enhancing Stability of the Gut Microbiota and Barrier Integrity and Reducing Inflammation.罗伊氏乳杆菌 SLZX19-12 通过增强肠道微生物群和屏障完整性的稳定性以及减少炎症来保护结肠免受感染。
Microbiol Spectr. 2022 Jun 29;10(3):e0212421. doi: 10.1128/spectrum.02124-21. Epub 2022 Jun 6.
艰难梭菌相关性结肠炎的非手术治疗时间延长与死亡率、并发症和费用增加有关。
Am J Surg. 2019 Jun;217(6):1042-1046. doi: 10.1016/j.amjsurg.2019.01.017. Epub 2019 Jan 24.
4
Clostridium difficile Colitis Prevention and Treatment.艰难梭菌相关性结肠炎的预防与治疗。
Adv Exp Med Biol. 2019;1125:139-146. doi: 10.1007/5584_2018_322.
5
Probiotics to Prevent Clostridium difficile Infection in Patients Receiving Antibiotics.益生菌预防接受抗生素治疗的患者发生艰难梭菌感染。
JAMA. 2018 Aug 7;320(5):499-500. doi: 10.1001/jama.2018.9064.
6
An enhanced Lactobacillus reuteri biofilm formulation that increases protection against experimental necrotizing enterocolitis.增强型罗伊氏乳杆菌生物膜配方,可提高对实验性坏死性小肠结肠炎的保护作用。
Am J Physiol Gastrointest Liver Physiol. 2018 Sep 1;315(3):G408-G419. doi: 10.1152/ajpgi.00078.2018. Epub 2018 May 31.
7
Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants.微生物制剂(益生菌)预防成人和儿童艰难梭菌感染的效果:6851 名参与者的个体患者数据荟萃分析。
Infect Control Hosp Epidemiol. 2018 Jul;39(7):771-781. doi: 10.1017/ice.2018.84. Epub 2018 Apr 26.
8
Probiotics for Prevention and Treatment of Clostridium difficile Infection.益生菌预防和治疗艰难梭菌感染。
Adv Exp Med Biol. 2018;1050:161-176. doi: 10.1007/978-3-319-72799-8_10.
9
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.用于预防成人和儿童艰难梭菌相关性腹泻的益生菌
Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4.
10
Probiotics for prevention of Clostridium difficile infection.用于预防艰难梭菌感染的益生菌
Curr Opin Gastroenterol. 2018 Jan;34(1):3-10. doi: 10.1097/MOG.0000000000000410.